08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Aerucin: Phase I data

An open-label, U.S. Phase I trial in 16 healthy volunteers showed that single ascending doses of <=20 mg/kg IV Aerucin led to no serious adverse events. This year, Aridis plans to start an international Phase...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Aerucin regulatory update

FDA granted Fast Track designation to Aridis’ Aerucin to treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The human IgG1 mAb against P. aeruginosa is in Phase I testing, with data expected next quarter....
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Aerucin: Phase I started

Aridis began an open-label, U.S. Phase I trial to evaluate single ascending doses of IV Aerucin in about 15 healthy adults. Aridis Pharmaceuticals Inc. , San Jose, Calif.   Product: Aerucin   Business: Infectious  ...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Aridis, Kenta deal

Aridis Pharmaceuticals LLC , San Jose, Calif.   Kenta Biotech Ltd. , Schlieren, Switzerland   Business: Infectious   Infectious disease company Aridis will acquire Kenta's portfolio of six anti-infective human mAbs and technologies for an...